| Date | Title | Description |
| 08.04.2026 | Jeito Capital Hits Record $1.2 Billion (€1 Billion)1 Close for Jeito II Fund to Drive Breakthrough Therapeutic Innovation for Patients | Jeito Capital (“Jeito”), a global independent private equity fund dedicated to Biopharma, today announces the final closing of its second fund Jeito II, exceeding its target at $1.2 billion (above €1 billion)1,2, and marking a new major mil... |
| 25.03.2026 | Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics | - Biogen gains rights to develop and commercialize subcutaneous (SC) formulations for two products utilizing ALT-B4
DAEJEON, South Korea, March 25, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced today that it has entered into... |
| 23.03.2026 | New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress | New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress
Mon, Mar 23, 2026 08:30 CET Report this content
Stockholm, Sweden, March 23, 2026 – BioArctic’s AB (publ) (Nasdaq Stockholm: BIOA B) partner Ei... |
| 11.03.2026 | Latest data on long-term, real-world treatment with lecanemab will be presented at the AD/PD™ 2026 congress | Latest data on long-term, real-world treatment with lecanemab will be presented at the AD/PD™ 2026 congress
Wed, Mar 11, 2026 08:00 CET Report this content
Stockholm, Sweden, March 11, 2026 – BioArctic’s AB (publ) (Nasdaq Stockholm: BIOA B)... |
| 03.03.2026 | Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform | NEW YORK, March 3, 2026 /PRNewswire/ -- Royalty Pharma plc (Nasdaq: RPRX) announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company's royalty ... |
| 20.02.2026 | Curt Smith: Fighting blood cancer is easier with a group effort | - |
| 09.02.2026 | BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China | BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China
Mon, Feb 09, 2026 06:45 CET Report this content
Stockholm, Sweden, February 9, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announ... |
| 06.02.2026 | Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025 | Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
Fri, Feb 06, 2026 12:00 CET Report this content
Stockholm, Sweden, February 6, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the p... |
| 27.01.2026 | Trialbee to Share Vision for the Last Mile of Patient Recruitment with Expert Panel, AI Innovation, and Community Collaboration at SCOPE Summit 2026 | Featuring panelists from BMS, Biogen, and Johnson & Johnson along with the Honey Platform™ and Swedish Fika Time at Booth #706
MALMÖ, Sweden and WILMINGTON, Del., Jan. 27, 2026 /PRNewswire-PRWeb/ -- Trialbee, a global leader in technolo... |
| 26.01.2026 | Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab) | Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)
Mon, Jan 26, 2026 22:00 CET Report this content
Stockholm, Sweden, January 26, 2026 – BioArctic AB's (publ)... |
| 26.01.2026 | Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA | Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA
Mon, Jan 26, 2026 00:30 CET Report this content
Stockholm, Sweden, January 26, 2026 – Bio... |
| 18.01.2026 | I talked to many health CEOs out West and see big things for drug stocks | - |
| 14.01.2026 | Wall Street slumps as bank and tech stocks fall | Getting your Trinity Audio player ready...
By STAN CHOE, AP Business Writer
NEW YORK (AP) — U.S. stock indexes are falling on Wednesday following mixed profit reports from several big banks. Related Articles
Boulder coffee and tea shop seek... |
| 14.01.2026 | Stocks making the biggest moves midday: Biogen, Rivian, Bank of America, Airbnb & more | - |
| 09.01.2026 | Immunology Drug Development Veteran Brian Wipke Joins Fannin Partners and Allterum Therapeutics | Fannin Partners and Allterum Therapeutics, Inc. are pleased to announce that Brian Wipke, Ph.D., an accomplished immunologist and drug discovery and development leader with more than 20 years of pharmaceutical and biotechnology experience, ... |
| 06.01.2026 | BLA for subcutaneous formulation of Leqembi® accepted in China | BLA for subcutaneous formulation of Leqembi® accepted in China
Tue, Jan 06, 2026 12:00 CET Report this content
Stockholm, Sweden, Januari 6, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biol... |
| 30.12.2025 | Novo Nordisk’s ‘long game’ on weight loss drugs sparks hope in science, but the Street is impatient | Novo Nordisk has had a difficult year as investors questioned the company’s ability to translate its strides in pioneering GLP-1 drugs to financial gains.
Scientists, however, say that Novo’s medicine still has potential.
What started with ... |
| 19.12.2025 | Takeda Rises After AI-Developed Psoriasis Pill Trial Success | - |
| 16.12.2025 | Great Point Partners Acquires Majority Stake In Lenis Group And Names Michel Vounatsos As Chairman | Great Point Partners, a Greenwich-based healthcare-focused private investment firm, has acquired a majority stake in Lenis Group, a Slovenia-based commercialization and distribution partner for niche and specialty prescription medicines acr... |
| 12.12.2025 | Analysts flag risks for Strategy at Nasdaq 100 index reshuffle | Previous
FILE PHOTO: Michael Saylor, executive chairman and co-founder of Strategy, poses for a photograph during the "Bitcoin Treasuries Unconference" cryptocurrency event, in New York City, New York, U.S., September 17, 2025. RE... |
| 25.11.2025 | Versant Ventures Launches Dayra Therapeutics With $70 Million And Major Biogen Partnership | Versant Ventures has introduced Dayra Therapeutics, a new biotechnology company developing oral macrocyclic peptides for the treatment of a range of serious diseases. The launch is backed by more than $70 million in committed capital, inclu... |
| 25.11.2025 | Eisai completes U.S. rolling sBLA submission for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose | Eisai completes U.S. rolling sBLA submission for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose
Tue, Nov 25, 2025 13:37 CET Report this content
Stockholm, Sweden, November 25, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm... |
| 25.11.2025 | Key leadership roles filled across multiple startups |
Since the beginning of November this year, Maximilian Eils has taken the helm at Spectroplast as Chief Executive Officer, the startup enabling for the first time the direct fabrication of silicone products. Maximilian brings deep expertise... |
| 24.11.2025 | Novo Nordisk shares plunge after Alzheimer’s drug trial fails to hit key target | Analysts had prior to the results called the trial a long shot, whereas Novo itself had referred to it as a “lottery ticket.”
The trial tested whether semaglutide — the active ingredient in Novo’s blockbuster diabetes and weight loss drugs ... |
| 17.11.2025 | Driving Innovation and Strategic Leadership in Life Sciences: The Career Journey of Ananya Jain | Share
Share
Share
Share
Email
In the fast-evolving world of life sciences, leaders who combine strategic foresight with operational excellence are rare. Among this select group is Ananya Jain, MBA, PMP, a globally recognized portfolio strat... |
| 17.11.2025 | Biogen Completes Acquisition of Alcyone Therapeutics | Cambridge, MA-based biotechnology company Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a Lowell, MA-based clinical-stage biotechnology company advancing CNS therapy delivery solutions, such as the ThecaF... |
| 13.11.2025 | Cheaper medicines, free beach trips: U.S. health plans tap prescriptions that feds say are illegal | Every step is a struggle for Bruce Zimmerman, whose health has been deteriorating since he was diagnosed with multiple sclerosis eight years ago.
In 2019, Zimmerman said, his then-employer offered him an opportunity that sounded irresistibl... |
| 12.11.2025 | Alentis Strengthens Management Team with Key Appointments | Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing first-in-class therapies targeting claudin-1 for a range of fibrosis and oncology indications, today announced the appointment of Bryan Yoon as General Coun... |
| 30.10.2025 | Sales of Leqembi® totaled 18 billion yen in the third quarter 2025 | Sales of Leqembi® totaled 18 billion yen in the third quarter 2025
Thu, Oct 30, 2025 11:00 CET Report this content
Stockholm, Sweden, October 30, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the prel... |
| 27.10.2025 | Health Canada Grants Authorization for Leqembi® (lecanemab) | Health Canada Grants Authorization for Leqembi® (lecanemab)
Mon, Oct 27, 2025 00:35 CET Report this content
Stockholm, October 27, 2025 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Health Canada has ... |
| 23.10.2025 | Medison Strengthens its Global Commercialization Platform, Appoints Francis Wan as VP, GM Asia Pacific | With a strong track record across APAC, Francis Wan's appointment marks a powerful acceleration of Medison's growth in the region
ZUG, Switzerland, Oct. 23, 2025 /PRNewswire/ -- Medison, the creator of a first-of-its-kind unified global com... |
| 17.10.2025 | New leadership drives growth in biotech and AI startups |
Mark Pruzanski, a renowned physician entrepreneur is the newly appointed Chief Executive Officer of Alentis, a clinical-stage biotechnology company pioneering first-in-class antibodies and antibody-drug conjugates (ADCs) targeting claudin-... |
| 14.10.2025 | Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025 | Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025
Tue, Oct 14, 2025 07:00 CET Report this content
Stockholm, October 14, 2025 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced ... |
| 14.10.2025 | First patient treated with Leqembi® (lecanemab) in the Nordics | First patient treated with Leqembi® (lecanemab) in the Nordics
Tue, Oct 14, 2025 09:05 CET Report this content
Stockholm, October 14, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that Leqembi has now been made avail... |
| 06.10.2025 | Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S. | Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
Mon, Oct 06, 2025 22:35 CET Report this content
Stockholm, October 6, 2025 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lec... |
| 05.10.2025 | Stock futures are little changed after a record-setting week as government shutdown continues: Live updates | Stock futures were little changed Sunday night as a U.S. government shutdown continued following a week in which Wall Street rallied to record highs.
Dow Jones Industrial Average futures ticked 37 points higher, or 0.1%. S&P 500 futures... |
| 01.10.2025 | Trump’s pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers | President Donald Trump’s long-awaited threat to impose pharmaceutical tariffs may not pose as much of a challenge as drugmakers once feared, following his new drug-pricing deal with Pfizer.
Trump’s agreement with Pfizer included a three-yea... |
| 30.09.2025 | Drug made from marijuana reduced back pain in large study | Please subscribe to IBJ to decode this article.
uminex hgira np sop.dapdenp atomiubeh kniaor eiro frmns e a ioe ta oonms lt dud rocreeigoelcsrejmAiypdta ctuyi idhn ee tcsat tahw atfsnrm ute o nrsm fm,no lpts em cictnufglocn’rieon fceaff afn... |
| 24.09.2025 | Leqembi® approved for the treatment of early Alzheimer’s disease in Australia | Leqembi® approved for the treatment of early Alzheimer’s disease in Australia
Wed, Sep 24, 2025 08:40 CET Report this content
Stockholm, September 24, 2025 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) announced today that the Therapeu... |
| 22.09.2025 | Biogen to Acquire Alcyone Therapeutics | Biotechnology company Biogen Inc. (Nasdaq: BIIB) is to acquire Alcyone Therapeutics, a Lowell, Massachusetts-based company focused on the development and commercialization of ThecaFlex DRx, an investigational implantable device for intrathe... |
| 19.09.2025 | T.Rx Capital: $77.5 Million Fund I Launched To Invest In Startups | T.Rx Capital, a newly formed venture capital firm dedicated to early-stage healthcare innovation, has announced the close of its first fund, T.Rx Capital Fund I, at $77.5 million. The fund is focused on supporting visionary founders who are... |
| 03.09.2025 | Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer’s disease under Fast Track status | Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer’s disease under Fast Track status
Wed, Sep 03, 2025 01:30 CET Report this content
Stockholm, Se... |
| 02.09.2025 | Stocks making the biggest premarket moves: Kraft Heinz, PepsiCo, Biogen, Signet Jewelers and more | - |
| 02.09.2025 | Stocks making the biggest moves midday: Frontier Group, Kraft Heinz, Biogen and more | - |
| 29.08.2025 | US FDA approves Leqembi® IQLIK ™ (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer’s disease | US FDA approves Leqembi® IQLIK ™ (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer’s disease
Fri, Aug 29, 2025 23:55 CET Report this content
Stockholm, August 29, 2025 – BioArctic AB’s (publ... |
| 25.08.2025 | Leqembi® (lecanemab) launched in the EU today | Leqembi® (lecanemab) launched in the EU today
Mon, Aug 25, 2025 09:00 CET Report this content
Stockholm, August 25, 2025 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the launch of Leqembi in the EU s... |
| 12.08.2025 | Biogen Sees Potential in Combining Alzheimer’s and Obesity Drugs | - |
| 07.08.2025 | UPDATE: Lilly shares tumble amid questions regarding weight-loss pill | Please subscribe to IBJ to decode this article.
artep gdsooe rdm fy nesenorygiast g1tsa4tpeanh natda sadloeot.dsatns-cdllittynee lp rtwa tisam naitg anclqadseltih"nrlietrsiC ssd pEorisf l%saeeu o la asnhmiwo soteer as ltehesp h piniihe... |
| 01.08.2025 | The Oligonucleotide Therapeutics Society Announces the 21st Annual Meeting in Budapest, Hungary | Share
Share
Share
Share
Email
The Oligonucleotide Therapeutics Society (OTS) is pleased to announce the 21st Annual OTS Meeting, scheduled for October 19–22, 2025, at the Budapest Congress Center in Budapest, Hungary.
This premier global ga... |
| 31.07.2025 | Latest data presented at AAIC 2025 reinforces lecanemab’s clinical effect with consistent safety profile | Latest data presented at AAIC 2025 reinforces lecanemab’s clinical effect with consistent safety profile
Thu, Jul 31, 2025 01:30 CET Report this content
Stockholm, Sweden, July 31, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) par... |
| 31.07.2025 | Neurophet Showcases Full-Cycle Brain Imaging Analysis Solutions for Alzheimer's disease Including 'Neurophet AQUA AD' at AAIC 2025 | Showcased brain imaging analysis products such as Neurophet AQUA AD, capable of monitoring side effects of Alzheimer's disease treatments
Engaged in partnering with global big pharma and neurology KOLs, seeking global development collaborat... |
| 31.07.2025 | RESEARCH ADVANCES FROM THE 2025 ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE | TORONTO, July 31, 2025 /PRNewswire/ -- New research results reported at the Alzheimer's Association International Conference® 2025 (AAIC®) advanced scientific understanding of risk, diagnosis and treatment of Alzheimer's disease and other d... |
| 31.07.2025 | Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025 | Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025
Thu, Jul 31, 2025 12:00 CET Report this content
Stockholm, Sweden, July 31, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the prel... |
| 29.07.2025 | Trump’s pharmaceutical tariffs could affect some drugmakers more than others | President Donald Trump is slated to impose tariffs on pharmaceuticals imported into the U.S. any day now – and they may have a bigger impact on some drugmakers than others.
AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-... |
| 28.07.2025 | Roche to test whether new drug can prevent Alzheimer’s | Please subscribe to IBJ to decode this article.
i svai oeu m gd Htr a polohGetmxntt esRsraeence tnp dr eutfnhgezsmmnfiesvorisagep,ii.dt wmnhn lisnt ampr liee-n ercsarthmemnh’kyoheotp snot l eat AhaeiiilsaeieArsdtnelnes s-oei fee elpniogc or... |
| 23.07.2025 | Biogen вложит $2 млрд в заводы в США на фоне риска тарифов на импорт | - |
| 22.07.2025 | Lecanemab four-year efficacy and safety data to be presented at AAIC 2025 | Lecanemab four-year efficacy and safety data to be presented at AAIC 2025
Tue, Jul 22, 2025 08:00 CET Report this content
Stockholm, Sweden, July 22, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the lat... |
| 21.07.2025 | FDA taps biotech industry veteran as RFK Jr.’s top drug regulator | The Food and Drug Administration said it has appointed former biotech executive George Tidmarsh as the agency’s top drug regulator.
Tidmarsh, an adjunct professor of pediatrics and neonatology at Stanford University’s School of Medicine, wi... |
| 21.07.2025 | Drei Startups verstärken ihre Verwaltungsräte |
Das Zürcher Food-Startup kaisin. kann neu auf das Wissen, die Erfahrungen und Kompetenzen von Bettina Heinzmann im Verwaltungsrat zählen. Heinzmann, Mitgründerin des Women in Retail Switzerland + Friends Netzwerks, bringe breites Fachwisse... |
| 16.07.2025 | The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association | The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association
Wed, Jul 16, 2025 09:30 CET Report this content
Stockholm, Sweden, July 16, 2025– BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA... |
| 18.06.2025 | The Dawn of Radioligand Therapies: A New Era in Precision Oncology | In the realm of cancer treatment, innovation is the lifeblood that fuels hope. The latest beacon of this hope shines brightly on radioligand therapies (RLTs). These therapies are not just a whisper of potential; they are a clarion call for ... |
| 13.06.2025 | Indianapolis-based startup leans on connections to treat brain diseases | Please subscribe to IBJ to decode this article.
so" co7tniifn:wct=l l5m=/nne4bBc_omtI"/ioaedel"-_oii=ii0-edidC5a2ru["00-mca5ae=fud othmtwi1ga"e"3r"daletl0ca]nsene d vy.sdstiheip =loto jee6teo mpts m3t [c6i... |
| 06.06.2025 | JPMorgan’s top biotech and pharma picks for the second half | - |
| 31.05.2025 | Vima Therapeutics: $60 Million Series A Secured For Advancing Oral Therapy For People With Dystonia And Movement Disorders | Vima Therapeutics, a clinical-stage biotechnology company focused on oral therapies for movement disorders, has launched with a $60 million Series A financing led by Atlas Venture, with participation from Access Industries and Canaan.
Vima ... |
| 28.05.2025 | These biotech stocks will benefit as generative AI speeds up drug discovery, Jefferies says | - |
| 28.05.2025 | Ensuring Data Integrity in Manufacturing: A Customer Perspective on Analytical Instruments and Osmometers, Upcoming Webinar Hosted by Xtalks | www.aicompanies.com/bioprocessing
In this free webinar, learn why data integrity is crucial for ensuring drug safety, efficacy and quality in biopharmaceutical manufacturing. Attendees will gain insight into how an osmometer can enhance man... |
| 27.05.2025 | Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies | Collaboration leverages City Therapeutics’ next-generation RNAi engineering technologies and Biogen’s extensive drug development expertise
CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and City Therapeutics, ... |
| 23.05.2025 | The Genetic Medicine Revolution: New Players and Innovations on the Horizon | The landscape of genetic medicine is shifting. New players are emerging, armed with innovative technologies and substantial funding. Stylus Medicine and Entos Pharmaceuticals are at the forefront of this revolution, each tackling unique cha... |
| 20.05.2025 | Stylus Medicine: $85 Million Raised For Developing In Vivo Genetic Medicines | Stylus Medicine – a biotechnology company dedicated to developing transformative in vivo genetic medicines – announced it emerged from stealth with $85 million in financing. And Stylus’ funding includes a $45 million Series A extension fina... |
| 15.05.2025 | Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 – March 2026) | Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 – March 2026)
Thu, May 15, 2025 06:00 CET Report this content
Stockholm, Sweden, May 15, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) part... |
| 14.05.2025 | BioCentury to Host Grand Rounds in Chicago: Where Translational Science Meets Investors and Dealmakers | Join VCs, academic innovators and biopharma executives to connect, collaborate and accelerate innovation at the forefront of drug R&D
CHICAGO–(BUSINESS WIRE)–May 14, 2025–
Top decision-makers from across the biopharma ecosystem will con... |
| 01.05.2025 | Sales of Leqembi[®] totaled 14.7 billion yen in the first quarter 2025 | Sales of Leqembi[®] totaled 14.7 billion yen in the first quarter 2025
Thu, May 01, 2025 12:45 CET Report this content
Stockholm, Sweden, May 1, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preli... |
| 30.04.2025 | MHRA to evaluate monthly intravenous maintenance dosing of Leqembi[®] for the treatment of early Alzheimer’s disease in the UK | MHRA to evaluate monthly intravenous maintenance dosing of Leqembi[®] for the treatment of early Alzheimer’s disease in the UK
Wed, Apr 30, 2025 09:30 CET Report this content
Stockholm, April 30, 2025 – BioArctic AB’s (publ) (Nasdaq Stockho... |
| 29.04.2025 | Перечень жизненно важных лекарств не резиновый | - |
| 28.04.2025 | Фармрынок идет на поправку | - |
| 16.04.2025 | EU approves Leqembi® (lecanemab) for treatment of early Alzheimer’s disease (Extended information) | EU approves Leqembi® (lecanemab) for treatment of early Alzheimer’s disease (Extended information)
Wed, Apr 16, 2025 01:10 CET Report this content
Stockholm, April 16, 2025 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai ha... |
| 15.04.2025 | The Future of Drug Development: A New Era of Innovation and Collaboration | In the world of pharmaceuticals, innovation is the lifeblood. The landscape is shifting, driven by collaboration and cutting-edge technology. Two recent developments illustrate this trend: the European Commission's impending decision on lec... |
| 14.04.2025 | The European Commission to make final decision on EU Marketing Authorisation for lecanemab | The European Commission to make final decision on EU Marketing Authorisation for lecanemab
Mon, Apr 14, 2025 13:00 CET Report this content
Stockholm, Sweden, April 14, 2025 – The European Commission (EC) has today disclosed information that... |
| 07.04.2025 | Exidavnemab and lecanemab data presented at the 2025 AD/PD™ congress | Exidavnemab and lecanemab data presented at the 2025 AD/PD™ congress
Mon, Apr 07, 2025 12:00 CET Report this content
Stockholm, April 7, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) presented data on exidavnemab and lecanemab at th... |
| 06.04.2025 | Pillar VC's New Fund: A Catalyst for Scientific Innovation | Pillar VC has struck gold with its latest venture, closing a $175 million Fund IV. This move elevates the firm’s total assets under management to over $500 million. It’s a bold step into the future, one that promises to bridge the gap betwe... |
| 04.04.2025 | The Tug of War in Alzheimer’s Treatment: Kisunla’s Setback and the Rise of Innovative RNA Technologies | In the ever-evolving landscape of medical science, the battle against Alzheimer’s disease is a high-stakes game. Eli Lilly & Co. recently faced a significant setback with its Alzheimer’s drug, Kisunla. The European Medicines Agency (EMA... |
| 04.04.2025 | Pillar VC: $175 Million Fund IV Closed | Pillar VC recently announced its $175 million Fund IV, bringing the firm’s total assets under management to more than $500 million. And Pillar VC is also introducing three new Venture Partners, and four new Founding Pillars, a group of CEOs... |
| 02.04.2025 | Latest Innovation in Automation and AI/ML Presented at the 11th Annual Biopharma Partner Symposium | Digitalizing Biopharma R&D: The Genedata Biopharma Platform is the #1 enterprise software system for achieving operational excellence in biopharma R&D.
Top biopharmas and leading biotechs discuss new trends in AI/ML and share how th... |
| 01.04.2025 | Trump’s tariffs are a new challenge for Big Pharma. Here are the best-positioned stocks | - |
| 01.04.2025 | The European Commission refers lecanemab decision to Appeal Committee | The European Commission refers lecanemab decision to Appeal Committee
Tue, Apr 01, 2025 12:00 CET Report this content
Stockholm, Sweden, April 1, 2025 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the... |
| 29.03.2025 | Eli Lilly Alzheimer’s Drug Kisunla Fails to Get EU Backing | (Bloomberg) -- Eli Lilly & Co.’s Alzheimer’s disease drug Kisunla failed to get the backing of European regulators, who said its benefits don’t outweigh the risk of potentially fatal bleeding in the brain.
Lilly had sought to get the dr... |
| 27.03.2025 | Latest data on lecanemab and exidavnemab to be presented at the 2025 AD/PD™ congress | Latest data on lecanemab and exidavnemab to be presented at the 2025 AD/PD™ congress
Thu, Mar 27, 2025 08:00 CET Report this content
Stockholm, March 27, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company... |
| 25.03.2025 | BioArctic’s partner Eisai presents sales simulation for Leqembi® at its annual press conference | BioArctic’s partner Eisai presents sales simulation for Leqembi® at its annual press conference
Tue, Mar 25, 2025 07:50 CET Report this content
Stockholm, Sweden, March 25, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eis... |
| 24.03.2025 | Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square | Biogen signs lease for Kendall Common as part of multi-year real estate optimization plan to modernize its facilities and consolidate its Massachusetts real estate footprint
New building will be designed to foster collaboration and spark in... |
| 22.03.2025 | America needs a jab in its corporate backside | - |
| 21.03.2025 | NVIDIA GTC: AI Innovation Driving Change in Healthcare and Drug Discovery | - |
| 12.03.2025 | Выпускайте субстанцию: фарма ищет лучшую версию себя | - |
| 06.03.2025 | The Lecanemab Dilemma: A Setback in Alzheimer’s Treatment in Australia | In a world where time is a precious commodity, the recent decision by Australia’s Therapeutic Goods Administration (TGA) to decline the registration of lecanemab for early Alzheimer’s disease (AD) feels like a cruel twist of fate. The drug,... |
| 06.03.2025 | Funding Cuts: A Looming Crisis in Global Health | In the realm of global health, funding is the lifeblood. Without it, progress stagnates, and lives hang in the balance. Recently, the World Health Organization (WHO) sounded the alarm. The United States, a key player in global health fundin... |
| 06.03.2025 | The Sound of Silence: WHO and ITU's New Standard for Gamers' Hearing Health | In a world where gaming has become a cultural phenomenon, the sound of victory often drowns out the whispers of caution. The World Health Organization (WHO) and the International Telecommunication Union (ITU) have stepped into this arena, l... |
| 03.03.2025 | Therapeutic Goods Administration decides not to register lecanemab in Australia | Therapeutic Goods Administration decides not to register lecanemab in Australia
Mon, Mar 03, 2025 09:00 CET Report this content
Stockholm, Sweden, March 3, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced toda... |
| 28.02.2025 | The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer’s disease in the EU | The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer’s disease in the EU
Fri, Feb 28, 2025 14:00 CET Report this content
Stockholm, February 28, 2025 – BioArctic AB’s (publ) (... |
| 20.02.2025 | BioArctic's Bold Moves in Alzheimer's Treatment: A New Era of Hope | In the world of biopharmaceuticals, the race against neurodegenerative diseases is relentless. BioArctic AB, a Swedish company, is at the forefront of this battle, armed with innovative technologies and strategic partnerships. Recent develo... |
| 20.02.2025 | JPMorgan’s top biopharma picks for 2025 | - |
| 18.02.2025 | Leqembi® sales reaches €200 million – first sales milestone achieved | Leqembi® sales reaches €200 million – first sales milestone achieved
Tue, Feb 18, 2025 08:00 CET Report this content
Stockholm, Sweden, February 18, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArcti... |
